Bridgebio Pharma (BBIO) Stock
Biotech developing precision medicines for genetic disorders and cancers. Here's the price, business snapshot, and what's worth knowing about Bridgebio Pharma in August 2026.
BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic disorders and selected cancers. With a market capitalisation of about $10.39bn, BridgeBio advances a diversified pipeline of small molecules and biologics, including several programmes in late-stage or registrational trials. Its value proposition centres on targeted therapies designed for specific genetic drivers, but progress is highly dependent on clinical trial outcomes and regulatory approvals. The company often uses partnerships and licensing to share risk and access expertise, while remaining R&D-intensive with limited commercial revenues to date. For investors this means potential high upside if key programmes succeed, counterbalanced by binary clinical risk, extended development timelines and possible financing needs. This is general educational information and not personalised financial advice; consider your objectives and tolerance for risk before acting.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BridgeBio Pharma's stock with a target price of $86.32, indicating positive outlook.
Financial Health
BridgeBio Pharma is performing strongly with high profits, substantial cash flow, and impressive revenue.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision medicines pipeline
Multiple programmes target genetically defined diseases and cancers, offering potential step-changes if trials succeed — though outcomes can be binary.
Milestone-driven value
Share price movements often hinge on trial readouts and approvals, creating catalysts but also short-term volatility.
Partnerships and reach
Collaborations and licensing help de‑risk development and expand capabilities, yet the company remains R&D-heavy and may need capital to progress programmes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
